Guidant loses in drug-coated stent decision
This article was originally published in Clinica
Guidant's attempt to get a drug-coated stent on the market has suffered a severe setback after a US district court judge ruled that the company's agreement with Cook - giving it access to the drug paclitaxel - was a "sham". The deal between the two companies violated an earlier co-exclusive agreement between Boston Scientific, Cook and Angiotech Pharmaceuticals for Angiotech's proprietary drug paclitaxel, the judge said in the ruling in favour of Boston Scientific.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.